Navigation Links
MAP Pharmaceuticals to Present Data on LEVADEX® at the 15th Congress of the International Headache Society
Date:6/23/2011

n adverse event was nausea at five percent compared with two percent for placebo.  There were no decreases in lung function, as measured by spirometry, between the active and placebo groups. 

About MigraineCommon symptoms of migraine include recurrent headaches, nausea, vomiting, photophobia (sensitivity to light) and phonophobia (sensitivity to sound).  According to the National Headache Foundation, most migraines last between four and 24 hours, but some last as long as three days.  On average, migraine sufferers experience three migraine attacks monthly, although 25 percent of them experience one or more attacks weekly.  The economic burden of migraine remains substantial despite existing treatments, with the direct and indirect costs of migraine in the United States estimated at over $20 billion annually.

About MAP Pharmaceuticals MAP Pharmaceuticals is an emerging biopharmaceutical company focused on developing and commercializing new therapies to address undermet patient needs in neurology.  The Company is developing LEVADEX, an orally inhaled investigational drug for the acute treatment of migraine.  The Company has reported positive results from its Phase 3 trial of LEVADEX and has submitted a New Drug Application to the U.S. Food and Drug Administration for the potential acute treatment of migraine in adults. MAP Pharmaceuticals has entered into a collaboration agreement with Allergan, Inc. to co-promote LEVADEX to neurologists and pain specialists in the U.S. The Company also applies its proprietary drug particle and inhalation technologies to generate new pipeline opportunities by enhancing the therapeutic benefits of proven drugs, while minimizing risk by capitalizing on their known safety, efficacy and commercialization history. Additional information about MAP Pharmaceuticals can be found at http://www.mappharma.com.

Forward-Looking StatementsIn add
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... Calif. , Nov. 21, 2014 In ... and Performance Scrubs carried out a new product development ... industry,s very first "limited edition" lab coat , ... female professors of surgery in the world. The new ... its unisex predecessors, with a sleek envelope collar, vertical ...
(Date:11/21/2014)... Nov. 21, 2014  Heated dialogue in recent months ... from cancer treatments to Gilead,s new hepatitis C drug ... the world questioning what it means to put a ... And while drug pricing is one of ... from both a general business and ethical standpoint – ...
(Date:11/21/2014)... 2014 Clementia Pharmaceuticals, ... dass die Europäische Arzneimittel-Agentur (European Medicines ... Orphan-Medizinprodukt an Palovarotene vergeben hat, den ... von Fibrodysplasia ossificans progressiva (FOP). FOP ... Krankheit, die von schmerzhaften, wiederkehrenden Episoden ...
Breaking Medicine Technology:Medelita Introduces Medical Industry's First Limited Edition Women's Designer Lab Coat 2"The Price of Global Health" Tackles Worldwide Drug-Pricing Debate 2"The Price of Global Health" Tackles Worldwide Drug-Pricing Debate 3"The Price of Global Health" Tackles Worldwide Drug-Pricing Debate 4"The Price of Global Health" Tackles Worldwide Drug-Pricing Debate 5Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 2Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 3
(Date:11/21/2014)... Angeles, CA (PRWEB) November 21, 2014 ... reference for the dental practice. It includes everything needed ... . , Procedure Coding with CDT , CDT 2015 ... provided from January 1, 2014 - December 31, 2014. ... report procedures and services on dental claims. There are ...
(Date:11/21/2014)... Even with years of experience under his belt, ... for growth, participating in two recent events for his State ... a networking event with the leaders of State Farm and ... latest and greatest in insurance news and products for his ... team (Stacy, Anthony, Reina and Jacob) as exhibitors at the ...
(Date:11/21/2014)... (PRWEB) November 21, 2014 CARE Surrogacy ... its intended parents — and at the same time enhancing ... sense of optimism for future parents across the globe, the ... , Prospective parents today are zoning in on the skyrocketing ... the encumbering costs, are individuals over-stressing clinical success rates ...
(Date:11/21/2014)... 21, 2014 According to a National ... June 11th, 2014, the inflating system found in certain ... airbag inflates. The force of inflation may cause the ... metal shards may pierce the airbag’s fabric and potentially ... , According to a Bloomberg Business Week article ...
(Date:11/21/2014)... 2014 Nature’s Sleep is excited to announce the ... contest calls for the creation of any type of art — ... encompasses sleep, a bed or a mattress. , “We had ... Vice President of Marketing for Nature’s Sleep, “that we decided to ... than 10,000 creative entries from some very talented artists all the ...
Breaking Medicine News(10 mins):Health News:PMIC Announces CDT PLUS! 2015, the Ultimate Coding Reference for Dentists and Oral Surgeons 2Health News:Kirk Martin Insurance Agency Goes Local and National with State Farm 2Health News:CARE Surrogacy Center Reports on its Multiple Measures of Success 2Health News:CARE Surrogacy Center Reports on its Multiple Measures of Success 3Health News:Takata Airbag Recall Class Action Lawsuit Resource Released by Florida Injury Attorney 2Health News:Takata Airbag Recall Class Action Lawsuit Resource Released by Florida Injury Attorney 3Health News:Nature’s Sleep Kicks Off their 2nd Art Of Sleep Contest 2
... The chances of suffering a stroke are linked to the ... system, a new study from Karolinska Institutet shows. The researchers ... mobilise the body,s own defence against arteriosclerosis and stroke. ... Frostegrd, has previously demonstrated that high levels of a certain ...
... taking action, study finds , FRIDAY, Feb. 12 ... opening in Canada Friday seem more on the ball ... activity enables elite athletes to see and react to ... new study finds. , Researchers analyzed the reaction time ...
... successfully inserted to reopen clogged coronary artery , THURSDAY, ... was said to be "in good spirits" Thursday evening ... two stents inserted into a clogged heart artery. , ... 2004, had been complaining of chest pains. , "Today ...
... , ... in Twin Cities , ... February 12, 2010 -- Ecumen an innovative non-profit senior housing, services and ... on its second senior housing community in Apple Valley and will manage The Seasons at ...
... ... to an underage passenger hurt in a vehicle crash after he left a party. ... Providence, RI (PRWEB) February 12, ... the liability homeowners face when they allow underage drinking in their homes., , ,Details of ...
... , ... Qigong has been called the secret of youth and longevity, and in his latest book, ... Eastern movements can slow the ageing process down and promote youthful skin from the inside ... (PRWEB) February 12, ...
Cached Medicine News:Health News:Ex-President Clinton Said To Be Fine After Heart Procedure 2Health News:Ex-President Clinton Said To Be Fine After Heart Procedure 3Health News:Ecumen Building Senior Housing in Apple Valley, Minnesota and Will Manage New Maplewood, Minnesota Property 2Health News:Ecumen Building Senior Housing in Apple Valley, Minnesota and Will Manage New Maplewood, Minnesota Property 3Health News:Rhode Island Settlement Reflects Homeowner Liability for Serving Alcohol to Those Under 21, Says Providence Lawyer Mark Gemma 2Health News:New Book Reveals How Qigong Could Be The Eastern Answer To Botox 2
... designed with the safety and comfort of the ... (also called SF-6) leaded glass, the industry standard ... as set for optical clarity, visible light transmission, ... is protecting your eyes, it also helps you ...
Panoramic styling that contours closely to the face and brow. Saddle bridge fits average to fuller noses. Adjustable temple hinge adjusts up or down, longer or shorter. Soft cushion behind ear for co...
Qualcraft™ Radiation Protection Eyewear, Metal, Bifocal. Provides maximum comfort and eye protection! Plano (nonprescription). Black with bronze temple bar....
QualCraft™ Radiation-Reducing Eyewear is 50% lighter than other protective eyewear. Manufactured for the ultimate combination of comfort, function, and protection....
Medicine Products: